Open Access<p>Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells</p>
Author(s) -
Marta Osrodek,
Michał Różański,
Małgorzata Czyż
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s263767
Subject(s) - vemurafenib , trametinib , melanoma , mapk/erk pathway , cancer research , insulin , medicine , pi3k/akt/mtor pathway , flow cytometry , apoptosis , pharmacology , biology , kinase , immunology , microbiology and biotechnology , metastatic melanoma , biochemistry
Despite the progress made in the clinical management of metastatic melanoma, a patient's response to treatment cannot be fully predicted, and intrinsic or acquired resistance that is developed in most melanoma patients warrants further research efforts. In addition to genetic factors, microenvironmental input should be considered to explain the diversity of response to treatment among melanoma patients. In this study, we evaluated the impact of insulin on patient-derived BRAF V600E melanoma cells, either untreated or treated with vemurafenib or trametinib, inhibitors of BRAF V600 and MEK1/2, respectively.